Аннотация
Гистиоцитоз клеток Лангерганса является редким пролиферативным заболеванием гистиоцитоподобных клеток, пик заболеваемости которого приходится на ранний детский возраст. Изолированный легочный гистиоцитоз из клеток Лангерганса является одной из форм данного заболевания, но обычно поражает молодых курильщиков в возрасте 30–40 лет. Отказ от курения является наиболее важной рекомендацией для таких пациентов. В статье приведены несколько клинических наблюдений и обзор литературы.
Ключевые слова: гистиоцитоз, гистиоцитоз из клеток Лангерганса, клинический случай.
Об авторе
В.В. Фомин, М.И. Митькина, Е.Н. Попова, Л.А. Пономарева, А.А. Чинова
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
ela12@yandex.ru
Список литературы
1. Overview of Histiocytic Disorders. Lipton JM. Zucker School of Medicine at Hofstra/Northwell; Carolyn Fein Levy, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Medically Reviewed. Dec 2021.
2. Emile JF, Abla O, Fraitag S et al. Weiss for the Histiocyte Society. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Review Article. Blood 2016; 127 (22): 2672–81. DOI: 10.1182/blood-2016-01-690636
3. Gulati N, Allen CE. Langerhans cell histiocytosis: Version 2021. Hematol Oncol 2021; 39 (Suppl. 1): 15–23.
4. Tillotson CV, Anjum F, Patel BC. Langerhans Cell Histiocytosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. 2022 Jul 18.
5. Xianglin Hu, Buhtoiarov IN, Yangbai Sun et al. Langerhans Cell Histiocytosis: A Population-based Study of Anatomical Distribution and Treatment Patterns. J Bone Oncology 2022 Oct.
6. Rodriguez-Galindo C. Clinical features and treatment of Langerhans cell histiocytosis. Acta Paediatr 2021; 110 (11): 2892–902. DOI: 10.1111/apa.16014
7. Guyot-Goubin A, Donadieu J, Barkaoui M et al. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000– 2004. Pediatr Blood Cancer 2008; 51 (1); 71–5.
8. Stålemark H, Laurencikas E, Karis J et al. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer 2008; 51 (1): 76–81.
9. Aricò M, Haupt R, Russotto VS et al. Langerhans cell histiocytosis in two generations: a new family and review of the literature. Med Pediatr Oncol 2001; 36 (2): 314–6.
10. Allen CE, Merad M, McClain KL. Langerhans-Cell Histiocytosis. New Eng J Med 2018; 379 (9): 856–68. DOI: 10.1056/NEJMra1607548
11. Ribeiro KB, Degar B, Antoneli CB et al. Ethnicity, race, and socioeconomic status influence incidence of Langerhans cell histiocytosis. Pediatr Blood Cancer 2015; 62 (6): 982–7. DOI: 10.1002/pbc.25404
12. Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood 2020; 135 (16): 1319–31.
13. Peckham-Gregory EC, Chakraborty R, Scheurer ME et al. A genomewide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood 2017; 130 (20): 2229–32. DOI: 10.1182/blood-2017-08-800565
14. Haupt R, Nanduri V, Calevo MG et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer 2004; 42 (5): 438–44. DOI: 10.1002/pbc.20021
15. Ma J, Laird JH, Chau KW et al. Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies. Cancer Med 2019; 8 (1): 58–66.
16. Egeler RM, Neglia JP, Puccetti DM et al. Association of Langerhans cell histiocytosis with malignant neoplasms. Cancer 1993.
17. Wu X, Chen S, Zhang LY et al. Langerhans cell histiocytosis of the thyroid complicated by papillary thyroid carcinoma: a case report and brief literature review. Medicine (Baltimore) 2017.
18. Moschovi M, Adamaki M, Vlahopoulos S, Rodriguez-Galindo C. Synchronous and metachronous thyroid cancer in relation to Langerhans cell histiocytosis; involvement of V600E BRAF-mutation? Pediatr Blood Cancer 2015; 62 (1): 173–4. DOI: 10.1002/pbc.25173
19. Pina-Oviedo S, Medeiros LJ, Li S et al. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. Mod Pathol 2017; 30: 734–44.
20. Egeler RM, Neglia JP, Aricò M et al; The LCH-Malignancy Study Group of the Histiocyte Society. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. Hematol Oncol Clin North Am 1998; 12 (2): 369–78.
21. Yokokawa Y, Taki T, Chinen Y et al. Unique clonal relationship between T-cell acute lymphoblastic leukemia and subsequent Langerhans cell histiocytosis with TCR rearrangement and NOTCH1 mutation. Genes Chromosomes Cancer 2015; 54 (7): 409–17. DOI: 10.1002/gcc.22252
22. Kato M, Seki M, Yoshida K et al. Genomic analysis of clonal origin of Langerhans cell histiocytosis following acute lymphoblastic leukaemia. Br J Haematol 2016; 175 (1): 169–72.
23. Badalian-Very G, Vergilio JA, Degar BA et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; 116: 1919–23.
24. Kobayashi M, Tojo A. Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment. Cancer Sci 2018; 109: 3707–13.
25. Lee LH, Gasilina A, Roychoudhury J et al. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight 2017; 2 (3): e89473.
26. Wang J, Xie L, Miao Yu et al. Adult pulmonary Langerhans cell histiocytosis might consist of two distinct groups: isolated form and extrapulmonary recidivism type. Ann Transl Med 2021; 9 (4): 357. DOI: 10.21037/atm-20-8141
27. Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood 2015; 126 (1): 26–35. DOI: 10.1182/blood-2014-12- 569301
28. Aricò M, Girschikofsky M, Généreau T et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003; 39 (16): 2341–8.
29. Vassallo R, Ryu JH, Schroeder DR et al. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Eng J Med 2002; 346: 484–90.
30. Schönfeld N, Dirks K, Costabel U, Loddenkemper R. Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheiten. A prospective clinical multicentre study on adult pulmonary Langerhans' cell histiocytosis. Sarc Vasc Diffuse Lung Dis 2012; 29 (2): 132–8.
31. Elia D, Torre O, Cassandro R et al. Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review. Eur J Int Med 2015; 26 (5): 351–6. DOI: 10.1016/j.ejim. 2015.04.001
32. Ronceray L, Pötschger U, Janka G et al; German Society for Pediatric, Hematology, and Oncology, Langerhans Cell Histiocytosis Study Group . Pulmonary involvement in pediatric-onset multisystem langerhans cell histiocytosis: effect on course and outcome. J Pediatr 2012.
33. Le Louet S, Barkaoui MA, Miron J et al. Childhood Langerhans cell histiocytosis with severe lung involvement: a nationwide cohort study. Orphanet J Rare Dis 2020; 15: 241. DOI: 10.1186/s13023-020- 01495-5
34. Tazi A, de Margerie C, Naccache JM et al. The natural history of adult pulmonary langerhans cell histiocytosis: a prospective multicentre study. Orphanet J Rare Dis 2015; 10: 30.
35. Radzikowska E, Błasińska-Przerwa K, Wiatr E et al. Pneumothorax in patients with pulmonary langerhans cell histiocytosis. Lung 2018; 196 (6): 715–20.
36. Le Guen P, Chevret S, Bugnet E et al. Management and outcomes of pneumothorax in adult patients with langerhans cell histiocytosis. Orphanet J Rare Dis 2019; 14 (1): 229.
37. Liu H, Osterburg AR, Flury J et al. MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary langerhans cell histiocytosis. JCI Insight 2020; 5 (4): e13204.
38. Picarsic J, Jaffe R. Nosology and pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 2015; 29 (5): 799–823.
39. Alayed K, Medeiros LJ, Patel KP et al. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases. Human Pathol 2016; 52: 61–7.
40. Mourah S, How-Kit A, Meignin V et al. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis. Eur Respir J 2016; 47: 1785–96.
41. Ozer E, Sevinc A,Ince D, Yuzuguldu R, Olgun N. BRAF V600E mutation: a significant biomarker for prediction of disease relapse in pediatric langerhans cell histiocytosis. Pediatr Dev Pathol 2019; 22: 449–55.
42. Lourenço J, Ferreira C, Marado D. Adult pulmonary Langerhans cell histiocytosis revealed by central diabetes insipidus: A case report and literature review. Mol Clin Oncol 2020 Oct.
43. Chiao-Yun Tsai, Hsu-Zhen-Dong Xu, Jiun-Yi Hsia et al. Spontaneous pneumothorax with pulmonary Langerhans cell histiocytosis (PLCH) in an adult heavy cigarette smoker – A case report. Respirol Case Rep 2022; 10 (4).
44. Elvan Çağlar Çıtak, Erdem Ak, Fatih Sağcan et al. Primary pulmonary Langerhans cell histiocytosis associated with smoking in an adolescent boy. Turk J Ped 2017.
45. Radzikowska E. Update on Pulmonary Langerhans Cell Histiocytosis. Front Med (Lausanne) 2020; 7: 582581.
46. Araujo B, Costa F, Lopes J, Castro R. Adult Langerhans Cell Histiocytosis with Hepatic and Pulmonary Involvement. Case Rep Radiol 2015; 2015: 536328.
47. Lian C, Lu Y, Shen S. Langerhans cell histiocytosis in adults: a case report and review of the literature. Oncotarget 2016; 7: 18678–83.
Для цитирования:Фомин В.В., Митькина М.И., Попова Е.Н., Пономарева Л.А., Чинова А.А. Гистиоцитоз из клеток Лангерганса. Клинический разбор в общей медицине. 2023; 4 (1): 19–26. DOI: 10.47407/kr2023.4.1.00185
Журнал предоставляет свободный доступ с возможностью использовать статьи в некоммерческих целях при условии указания авторства в рамках лицензии CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ru)